COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) Receives Average Recommendation of “Moderate Buy” from Analysts

COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) has been assigned a consensus recommendation of “Moderate Buy” from the ten ratings firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, seven have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $16.1111.

A number of brokerages have issued reports on CMPS. Morgan Stanley lifted their price target on COMPASS Pathways from $10.00 to $11.00 and gave the stock an “overweight” rating in a report on Wednesday, November 5th. Lifesci Capital upgraded COMPASS Pathways to a “strong-buy” rating in a research report on Thursday, February 12th. Weiss Ratings restated a “sell (d-)” rating on shares of COMPASS Pathways in a research report on Wednesday, January 21st. Royal Bank Of Canada raised their price target on COMPASS Pathways from $16.00 to $21.00 and gave the company an “outperform” rating in a report on Friday, January 23rd. Finally, Compass Point set a $15.00 target price on shares of COMPASS Pathways in a research report on Thursday, February 12th.

Key COMPASS Pathways News

Here are the key news stories impacting COMPASS Pathways this week:

• Positive Sentiment: COMP360 met the primary endpoint in a late‑stage (Phase 3) study, driving optimism about regulatory and commercial prospects for the psilocybin therapy. This is the main catalyst for the rally. Compass Pathways’ depression treatment meets main goal in late‑stage study
• Positive Sentiment: Compass announced it will report new clinical data from two ongoing Phase 3 trials (COMP005 and COMP006) and provided a timeline for additional Phase 3 results, reinforcing near‑term news flow that supports further upside. Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials
• Positive Sentiment: Market activity shows heightened bullish positioning: unusually large call option volume (over 10,000 calls) and extremely heavy equity volume suggest speculative and institutional buying around the trial news, which amplified the stock move. (Internal trading/activity reports)
• Neutral Sentiment: Public and media coverage (Investing.com, PharmaLetter, MSN) amplified investor attention; press coverage supports momentum but doesn’t guarantee regulatory approval or commercial success. Compass Pathways stock soars after positive Phase 3 trial results
• Neutral Sentiment: Reported short‑interest data in the filings appears erroneous (0 shares / NaN changes) and is unreliable as an indicator of bearish positioning or squeeze potential at present.
• Neutral Sentiment: Third‑party analyst commentary and forecasts (e.g., Lifesci Capital coverage) exist but are secondary to the actual trial readouts for near‑term price action. What is Lifesci Capital’s Forecast for CMPS FY2025 Earnings?
• Negative Sentiment: Compass launched a proposed $150M public offering of ADSs (and pre‑funded warrants), which can dilute existing shareholders and may cap near‑term upside despite the positive data. Investors should weigh dilution risk against trial progress. Compass Pathways Launches Proposed $150.0 Million Public Offering

Hedge Funds Weigh In On COMPASS Pathways

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Persistent Asset Partners Ltd acquired a new stake in COMPASS Pathways during the 4th quarter valued at approximately $38,000. Advisory Services Network LLC bought a new position in COMPASS Pathways in the third quarter worth about $41,000. China Universal Asset Management Co. Ltd. grew its stake in COMPASS Pathways by 46.7% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 18,272 shares of the company’s stock worth $51,000 after buying an additional 5,817 shares during the last quarter. BIT Capital GmbH bought a new stake in COMPASS Pathways in the 3rd quarter valued at about $54,000. Finally, Conservest Capital Advisors Inc. increased its position in COMPASS Pathways by 32.5% in the 2nd quarter. Conservest Capital Advisors Inc. now owns 20,363 shares of the company’s stock valued at $57,000 after acquiring an additional 5,000 shares during the period. 46.19% of the stock is owned by institutional investors and hedge funds.

COMPASS Pathways Stock Performance

NASDAQ:CMPS opened at $7.63 on Wednesday. The company’s 50-day moving average is $6.77 and its two-hundred day moving average is $5.89. COMPASS Pathways has a 1-year low of $2.25 and a 1-year high of $8.80. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.23 and a quick ratio of 1.23. The firm has a market capitalization of $732.63 million, a price-to-earnings ratio of -2.81 and a beta of 1.92.

About COMPASS Pathways

COMPASS Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, COMPASS Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.